Previously known as Celtrix Pharmaceuticals Inc and then as Insmed Pharmaceuticals Inc, the current firm - dba Insmed Incorporated - is a biopharmaceutical company focused on the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders. Quite active in the SBIR arena in the period mid-90's through 2000, once the firm went public and. increased employment, they effcetively ceased SBIR involvement. With operations in New Jersey, but also having facilities in Colorado, the firm is structured around correcting metabolic defects in the human body by replacing key regulatory molecules in a physiologically relevant fashion. Insmed is developing novel therapeutics for the treatment of seriously debilitating, degenerative conditions primarily associated with severe trauma, chronic diseases or aging. The Company's focus is on regenerating lost tissue and metabolic processes essential for the patient's health and quality of life. Ongoing product development programs target severe osteoporosis (recovery from hip fracture surgery), traumatic burns and diabetes. Other potential indications include protein-wasting diseases associated with cancer, AIDS, advanced kidney failure and other life-threatening conditions. The Company's development focus is on SomatoKine, a naturally occurring complex comprised of the anabolic hormone insulin-like growth factor-I (IGF-I) and its primary binding protein, BP3.
